AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial

AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson’s disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with early Parkinson’s disease. The trial met its primary endpoint – patients treated with tavapadon experienced a statistically significant reduction from baseline compared to placebo in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale Parts II and III combined score at week 26.1 The TEMPO-2 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living in the tavapadon group (5-15 mg) compared to placebo at week 26 “The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 partial agonist for the treatment of Parkinson’s disease,” said Primal Kaur, M.D., MBA, senior vice president, immunology, neuroscience, eye care and specialty development, AbbVie. “With these data in hand, we look forward to working with regulatory agencies to assess next steps, bringing us one step closer to providing tavapadon for those living with this chronic, debilitating disease.” The safety profile observed in the TEMPO-2 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.